Alkyl-lysophospholipids

Alky-lysophospholipids (ALP) are synthetic analogues of lysophosphatidylcholines (LPC), also called lysolecithins. They are synthesized by replacing the acyl-group within the LPC with an alkyl-group.[1] They are in contrast to LPC metabolically very stable.[1][2] They have anti-neoplastic (“anti-cancer”)[1] and immune modulating effects.[2] Their anti-tumor effects are due to modulation of intracellular signalling pathways, inducing apoptosis.[3] It is highly selective, sparing healthy cells.[2] Several like edelfosine, miltefosine and perifosine are under research and development as drugs against cancer and other diseases.

References

  1. 1 2 3 Munder, PG; Modolell M; Adreesen R; Weltzien HU; Westphal O (1979). "Lysophosphatidylcholine (Lysolecithin) and its Synthetic Analogues. Immunemodulating and Other Biologic Effects". Springer Seminars in Immunopathology. 203 (2): 187–203. doi:10.1007/BF01891668. S2CID 42907729.
  2. 1 2 3 Houlihan, W; Lohmeyer M; Workman P; Cheon SH (1995). "Phospholipid antitumor agents". Medicinal Research Reviews. 15 (3): 157–223. doi:10.1002/med.2610150302. PMID 7658750. S2CID 6997551.
  3. ↑ van Blitterswijk, W; Verheij M (2008). "Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects". Current Pharmaceutical Design. 14 (21): 2061–74. doi:10.2174/138161208785294636. PMID 18691116.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.